Shots:

• The approval is based on P-lll SUNBEAM & RADIANCE part B study which involves the assessing of Zeposia (0.92mg and 0.46 mg) vs Avonex (qw- IM) in 1-346 & 1313 patients with RMS for 12 & 24mos. across 158 & 150 sites in 20 & 21 countries respectively
• Result: relative reduction in ARR (48% & 38%); absolute ARR (0.18 vs 0.35 & 0.17 vs 0.28). reduction in number of T1– weighted GdE (0.16 vs 0.43 & 0.18 vs 0.37); reduction in enlarging T2 brain lesions (1.47 vs 2.84 & 1.84 vs 3.18) respectively
• Zeposia is the only first line S1P receptor modulator approved in Canada for the treatment of RRMS- acts by decreasing the frequency of clinical exacerbations

Ref: News Wire Canada | Image: BMS